HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled sel-tagged affibody molecule

Journal of Nuclear Medicine

Volumn 53, Issue 9, 2012, Pages 1446-1453

  Wållberg, Helena ^a   Grafström, Jonas ^b   Cheng, Qing ^b   Lu, Li ^b,c   Ahlzén, Hanna Stina Martinsson ^b   Samén, Erik ^b,c   Thorell, Jan Olov ^b,c   Johansson, Katarina ^b   Dunås, Finn ^d   Olofsson, Maria Hägg ^b   Stone Elander, Sharon ^b,c   Arnér, Elias S J ^b   Ståhl, Stefan ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Affibody AB   (Sweden)

Author keywords

11C; Affibody molecule; Positron emission tomography; Sel tag; Selenium

Indexed keywords

CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; RADIOISOTOPE; TETRAPEPTIDE; TRACER;

ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DOSIMETRY; HUMAN; IN VIVO STUDY; NUCLEAR MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; XENOGRAFT;

ANIMALS; CARBON RADIOISOTOPES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; MICE; MODELS, MOLECULAR; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SELENOCYSTEINE; TIME FACTORS;

EID: 84866162512     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102194     Document Type: Article

References (37)

1. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol. 2010;33:186-195.
2. O'Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. Molecular assays in breast cancer pathology. Pathology. 2011;43:116-127.
3. Capala J, Bouchelouche K. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol. 2010;22:559-566.
4. Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(suppl 3):S66-S73.
5. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
6. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
7. Serdons K, Verbruggen A, Bormans GM. Developing new molecular imaging probes for PET. Methods. 2009;48:104-111.
8. Tolmachev V, Stone-Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochim Biophys Acta. 2010;1800:487-510.
9. 11C-acetate. J Nucl Med. 2003;44:556-558.
10. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
11. 11C. Nat Protoc. 2006;1:604-613.
12. Johansson L, Chen C, Thorell JO, et al. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat Methods. 2004;1:61-66.
13. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. 1997;15:772-777.
14. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
15. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861-2871.
16. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006;66:4339-4348.
17. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol. 2010;11:581-589.
18. 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
19. 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37:613-622.
20. 111In-labelled analogue. Eur J Nucl Med Mol Imaging. 2010;37:1356-1367.
21. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem. 2008;19:235-243.
22. HER2:2395, with C-terminally engineered cysteine. J Nucl Med. 2009;50:781-789.
23. 11C]methane. Appl Radiat Isot. 1997;48:153-157.
24. Tran TA, Rosik D, Abrahmsen L, et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging. 2009;36:1864-1873.
25. 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem. 2008;19:569-573.
26. Snyder WS, Ford MR, Warner GG, Watson SB. "S," Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD pamphlet 11. New York, NY: Society of Nuclear Medicine; 1975.
27. Xu X, Zhou Q, Korfmacher WA. Development of a low volume plasma sample precipitation procedure for liquid chromatography/tandem mass spectrometry assays used for drug discovery applications. Rapid Commun Mass Spectrom. 2005;19:2131-2136.
28. Fayad W, Brnjic S, Berglind D, et al. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. Int J Cancer. 2009;125:2450-2455.
29. Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38:531-539.
30. 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging. 2008;35:2245-2255.
31. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA. 2010;107:15039-15044.
32. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417-425.
33. Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60:1319-1328.
34. 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J Nucl Med. 2011;52:461-469.
35. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812-818.
36. Zhu A, Lee D, Shim H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol. 2011;38:55-69.
37. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm. 2010;25:375-385.